登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H36N2O2
化学文摘社编号:
分子量:
372.54
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
非那雄胺, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
SMILES string
[H][C@@]12CC[C@@]3([H])[C@]4([H])CC[C@H](C(=O)NC(C)(C)C)[C@@]4(C)CC[C@]3([H])[C@@]1(C)C=CC(=O)N2
InChI key
DBEPLOCGEIEOCV-WSBQPABSSA-N
grade
pharmaceutical primary standard
API family
finasteride
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... SRD5A2(6716)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
选择性 5α-还原酶抑制剂；抗雄激素。
Application
Finasteride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
法规信息
涉药品监管产品
此项目有
Sarah L Hulin-Curtis et al.
Future oncology (London, England), 6(12), 1897-1913 (2010-12-15)
Incidences of prostate cancer in most countries are increasing owing to better detection methods; however, prevention with the use of finasteride, a very effective steroid 5α-reductase type II inhibitor, has been met with mixed success. A wide interindividual variation in
Manlio A Goetzl et al.
Nature clinical practice. Urology, 3(8), 422-429 (2006-08-12)
Prostate cancer chemoprevention involves the use of natural and/or synthetic agents that inhibit or reverse the development of precancerous lesions or delay progression of these lesions to invasive disease. The recent completion of the first Phase III trial for prostate
Stephen M Stout et al.
The Annals of pharmacotherapy, 44(6), 1090-1097 (2010-05-06)
To review available evidence on the safety and efficacy of finasteride in the treatment of alopecia in women. A literature search was conducted through PubMed (1948-March 2010) and MEDLINE (1950-March 2010) using the search terms finasteride and alopecia. References cited
Sergio Vañó-Galván et al.
Journal of the American Academy of Dermatology, 70(4), 670-678 (2014-02-11)
To our knowledge, there are no large multicenter studies concerning frontal fibrosing alopecia (FFA) that could give clues about its pathogenesis and best treatment. We sought to describe the epidemiology, comorbidities, clinical presentation, diagnostic findings, and therapeutic choices in a
Cosimo De Nunzio et al.
Expert opinion on drug metabolism & toxicology, 4(12), 1561-1568 (2008-12-02)
The development and introduction in clinical practice of finasteride, the first potent inhibitor of steroid 5-alpha-reductase that inhibits the conversion of testosterone to its active form dihydroxytestosterone, has created the possibility to prevent and treat prostatic disorder by manipulating and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持